Because TRK overexpression is present in gynecological cancers, and particularly TRK fusion has been described in cervical and uterine cancer (143, 144), the use of TRK inhibitors could be beneficial in these kinds of neoplasms. This evidence concerns the gene NTRK1 and neoplasm.